Form 4: Catalyst Pharmaceuticals Executive Exercises Options and Sells Shares for Tax Purposes

Brian Elsbernd, Chief Compliance/Legal Officer at Catalyst Pharmaceuticals, exercised stock options and sold a portion of the acquired shares for tax purposes.

Summary

• Brian Elsbernd, the Chief Compliance/Legal Officer of Catalyst Pharmaceuticals, executed transactions involving the company's stock on November 26, 2024.
• He exercised options to purchase 60,000 shares of common stock at a price of $4.01 per share.
• Following the exercise of options, he sold 13,256 shares of common stock at prices of $21.65 and $21.577 per share.
• The sales were conducted to cover tax obligations and the cost of exercising the options.
• After these transactions, Mr. Elsbernd directly owns 171,177 shares of common stock and 1,095,010 options to purchase common stock.

Sentiment

Score: 7

Explanation: The document reflects routine executive transactions, which are neither positive nor negative for the company's outlook. The executive's continued holding of a significant number of shares and options is a positive sign.

Positives

• The executive's continued holding of a significant number of shares and options indicates confidence in the company's future.
• The transactions were explicitly stated to be for tax purposes and not due to any disagreement with the company.

Management Comments

• Mr. Elsbernd remains an executive officer of the Company.
• The sales were not a result of a disagreement with the Company.

Industry Context

This is a routine filing related to executive stock option exercises and sales, which is common in publicly traded companies. It does not indicate any unusual activity or trend within the pharmaceutical industry.

Comparison to Industry Standards

• Executive stock option exercises and sales are a standard practice in publicly traded companies, including those in the pharmaceutical sector.
• The timing and pricing of these transactions are typical for executives managing their personal finances and tax obligations.
• The number of shares and options involved are within the expected range for an executive at this level.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine executive actions.
• The executive's continued employment and share ownership should reassure stakeholders.

Key Dates

Keywords

Catalyst Pharmaceuticals, stock options, insider trading, executive compensation, share sales, Form 4, Brian Elsbernd